KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Interest Expenses (2016 - 2026)

Abbott Laboratories' Interest Expenses history spans 18 years, with the latest figure at $174.0 million for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 32.82% to $174.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $536.0 million, a 2.37% decrease, with the full-year FY2025 number at $493.0 million, down 11.81% from a year prior.
  • Interest Expenses hit $174.0 million in Q1 2026 for Abbott Laboratories, up from $120.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for ABT hit a ceiling of $174.0 million in Q1 2026 and a floor of $120.0 million in Q4 2025.
  • Historically, Interest Expenses has averaged $142.4 million across 5 years, with a median of $141.0 million in 2022.
  • Biggest five-year swings in Interest Expenses: dropped 14.79% in 2025 and later soared 32.82% in 2026.
  • Tracing ABT's Interest Expenses over 5 years: stood at $154.0 million in 2022, then rose by 3.25% to $159.0 million in 2023, then decreased by 14.47% to $136.0 million in 2024, then fell by 11.76% to $120.0 million in 2025, then soared by 45.0% to $174.0 million in 2026.
  • Business Quant data shows Interest Expenses for ABT at $174.0 million in Q1 2026, $120.0 million in Q4 2025, and $121.0 million in Q3 2025.